Skin Reactions Related to Thoracic Implantable Chamber Dressings
ConditionSkin Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorInstitut Curie
Prospective, multicenter cohort of 500 patients newly treated with systemic chemotherapy with CCI. The main objective of this study is to measure the incidence of skin reactions related to thoracic implantable chamber dressings.
Patients over 18 years of age
New chemotherapy patients (1st line of treatment only)
Thoracic PAC
PICC Line and femoral PAC;
Patients undergoing treatment with bi-specific antibodies (e.g. tebentafusp);
Disunion requiring treatment
Patients treated for hematological cancer;